Ashman, who was announced as the successor to incumbent CEO Dr Cath O'Neill at the end of March, previously served as the director of sales and marketing at FTSE 100-listed Smith & Nephew PLC (LON:SN.) in its wound care, casting and bandaging division.
SkinBio said Ashman’s appointment to the board would allow him to gain an understanding of the business while O’Neill would focus on the company’s scientific developments and ongoing commercial discussions.
"Stuart's appointment as a director adds further commercial capability to the board. He has a considerable network within the medtech and life science industries and he has the experience and drive to take us forward on the next stage of the company's development," said Martin Hunt, the company’s non-executive chairman.
O’Neill will likely be turning her attention to the group’s first human study for its SkinBiotix cream, with data last week showing the product had produced a statistically significant increase in skin hydration for the under 50s cohort and a small, but statistically significant decrease in transepidermal water loss at day 29 in the over 60s cohort.
At the time, O’Neill said there was “a lot of scope” for the company to further optimise the formulation of the cream to make it more suitable for different age groups.
In early trading on Thursday, SkinBio shares were down 1.4% at 17.7p.
-- Adds share price --